AKAmeya Kasture

Ameya Kasture

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article

Previous Organizations / Institutes

The organizations / institutes from the scholar's other articles in the past ten years


Ameya Kasture has a total of 75 co-authors. Here are the top co-authors by number of shared publications:

  • Sonja Sucic

    Institute of Pharmacology, Medical University of Vienna, Vienna, Austria

    11 shared publications
  • Michael Freissmuth

    Institute of Pharmacology, Center of Physiology and Pharmacology, Medical University of Vienna, Vienna, Austria

    9 shared publications
  • Ali El-Kasaby

    Institute of Pharmacology, Medical University of Vienna, Austria

    6 shared publications
  • Thomas Hummel

    Department of Neurosciences and Developmental Biology, University of Vienna, Vienna, Austria

    6 shared publications
  • Sanjay Kasture

    Pinnacle Biomedical Research Institute, Bhopal, India

    4 shared publications
  • H. M. Mazhar Asjad

    From the Institute of Pharmacology and the Gaston H. Glock Research Laboratories for Exploratory Drug Development, Center of Physiology and Pharmacology, Medical University of Vienna, A-1090 Vienna, Austria and

    3 shared publications

Latest Publications

  • Open Access

    From dual norepinephrine–dopamine reuptake inhibition to selective dopamine reuptake inhibitors: a case of aromatically substituted N ,2-cyclopentylamines

    by Majlen A. Dilweg, Willem Jespers, Ameya S. Kasture, Rongfang Liu, Tamara A. M. Mocking, Jelle G. van der Ploeg, Adrianus M. M. Baselier, Gerard J. P. van Westen, Thomas Hummel, Sonja Sucic, et al.

    A novel series of N ,2-cyclopentylamine-based dopamine reuptake inhibitors was developed from earlier dual inhibitors. MAT selectivity was assessed in vitro and rationalized in silico . In vivo efficacy was shown in fruit fly locomotor assays.

  • Open Access

    Rescue of Epilepsy‐Associated Mutations of the Highly Conserved Glycine Residue 443 in the Human GABA Transporter 1

    by Nikita Shah, Vasylyna Kovalchuk, Rocco Zerlotti, Kim Cole, Andre Bazzone, Harald H. Sitte, Thomas Hummel, Ameya S. Kasture, Sonja Sucic

    The human γ‐aminobutyric acid (GABA) transporter 1 (hGAT‐1) plays a pivotal role in synaptic neurotransmission by facilitating the clearance of GABA from the synaptic cleft. Pathogenic mutations in the SLC6A1 gene encoding hGAT‐1 have been implicated in a spectrum of neurodevelopmental disorders, including epilepsy, autism spectrum disorder, intellectual disability, and developmental delay. Here, we elucidate the molecular and functional consequences of disease‐associated mutations affecting the highly conserved glycine residue at position 443 (G443) in hGAT‐1. Through a combination of in vitro biochemical analyses, ion flux assays, and pharmacological profiling in HEK293 cells, alongside in vivo studies in Drosophila melanogaster , we demonstrate that substitutions of G443 to aspartate (G443D) or valine (G443V) result in complete abolishment of GABA transport. This severe impairment stems from distinct disruptions in protein folding and trafficking. In particular, G443V is fully retained in the endoplasmic reticulum (ER), as substantiated by de‐glycosylation assays indicating exclusively core‐glycosylated protein bands and confocal co‐localization with the ER chaperone calnexin. The G443D variant, on the other hand, exhibits partial trafficking to the plasma membrane, confirmed by the presence of maturely glycosylated bands, albeit at significantly reduced expression levels relative to the wild type transporter. Treatment with glycerol and 4‐phenylbutyrate (4‐PBA) successfully restored both surface expression and GABA uptake activity of the G443 mutants. Our findings highlight the potential of small‐molecule chaperones as interventions for ameliorating protein misfolding and functional deficits in hGAT‐1‐associated pathologies.


  • Open Access

    Allosteric Inhibition and Pharmacochaperoning of the Serotonin Transporter by the Antidepressant Drugs Trazodone and Nefazodone

    by Ali El-Kasaby, Danila Boytsov, Ameya Kasture, Günther Krumpl, Thomas Hummel, Michael Freissmuth, Walter Sandtner

    The antidepressants trazodone and nefazodone were approved some four and three decades ago, respectively. Their action is thought to be mediated - at least in part - by inhibition of the serotonin transporter (SERT/SLC6A4). Surprisingly, their mode of action on SERT has not been characterized. Here we show that - similar to the chemically related drug vilazodone - trazodone and nefazodone are allosteric ligands, which inhibit uptake by and transport-associated currents through SERT in a mixed-competitive and non-competitive manner, respectively. Contrary to noribogaine and its congeners, all three compounds preferentially interact with the Na+-bound outward-facing state of SERT. Nevertheless, they act as pharmacochaperones and rescue the folding-deficient variant SERT-P601A/G602A. The vast majority of disease-associated point mutations of SLC6 (solute carrier-6) family members impair folding of the encoded transporter proteins. Our findings indicate that their folding defect can be remedied by targeting allosteric sites on SLC6 transporters. Significance Statement The serotonin transporter is a member of the solute carrier 6 family and is the target of numerous antidepressants. Trazodone and nefazodone have long been used as antidepressants. Here we show that their inhibition of the serotonin transporter digressed from the competiti­ve mode seen with other antidepressants. Trazodone and nefazodone rescued a folding-deficient variant of the serotonin transporter. This finding demonstrates that folding defects of mutated solute carrier-6 family members can also be corrected by allosteric ligands.


  • Open Access

    Prolongation of metallothionein induction combats Aß and α-synuclein toxicity in aged transgenic Caenorhabditis elegans

    by Dagmar Pretsch, Judith Maria Rollinger, Axel Schmid, Miroslav Genov, Teresa Wöhrer, Liselotte Krenn, Mark Moloney, Ameya Kasture, Thomas Hummel, Alexander Pretsch

    Neurodegenerative disorders (ND) like Alzheimer’s (AD), Parkinson’s (PD), Huntington’s or Prion diseases share similar pathological features. They are all age dependent and are often associated with disruptions in analogous metabolic processes such as protein aggregation and oxidative stress, both of which involve metal ions like copper, manganese and iron. Bush and Tanzi proposed 2008 in the ‘metal hypothesis of Alzheimer’s disease’ that a breakdown in metal homeostasis is the main cause of NDs, and drugs restoring metal homeostasis are promising novel therapeutic strategies. We report here that metallothionein (MT), an endogenous metal detoxifying protein, is increased in young amyloid ß (Aß) expressing Caenorhabditis elegans, whereas it is not in wild type strains. Further MT induction collapsed in 8 days old transgenic worms, indicating the age dependency of disease outbreak, and sharing intriguing parallels to diminished MT levels in human brains of AD. A medium throughput screening assay method was established to search for compounds increasing the MT level. Compounds known to induce MT release like progesterone, ZnSO4, quercetin, dexamethasone and apomorphine were active in models of AD and PD. Thioflavin T, clioquinol and emodin are promising leads in AD and PD research, whose mode of action has not been fully established yet. In this study, we could show that the reduction of Aß and α-synuclein toxicity in transgenic C. elegans models correlated with the prolongation of MT induction time and that knockdown of MT with RNA interference resulted in a loss of bioactivity.


  • Open Access

    Rescue by 4-phenylbutyrate of several misfolded creatine transporter-1 variants linked to the creatine transporter deficiency syndrome

    by Ali El-Kasaby, Ameya Kasture, Florian Koban, Matej Hotka, Hafiz M.M. Asjad, Helmut Kubista, Michael Freissmuth, Sonja Sucic


  • Open Access

    Distinct contribution of axonal and somatodendritic serotonin transporters in drosophila olfaction

    by Ameya Sanjay Kasture, Daniela Bartel, Thomas Steinkellner, Sonja Sucic, Thomas Hummel, Michael Freissmuth


  • Open Access

    Evaluation of oxidative stress mechanisms and the effects of phytotherapic extracts on Parkinson's disease Drosophila PINK1 B9 model

    by Biancamaria Baroli, Eleonora Loi, Paolo Solari, Ameya Kasture, Loredana Moi, Patrizia Muroni, Sanjay Kasture, Maria Dolores Setzu, Anna Liscia, Patrizia Zavattari

    Oxidative stress is commonly observed in both idiopathic and genetic cases of Parkinson's disease (PD). It plays an important role in the degeneration of dopaminergic neurons, and it has been associated with altered telomere length (TL). There is currently no cure for PD, and extracts of antioxidative plant, such as Mucunα pruriens and Withania somnifera , are commonly used in Ayurveda to treat patients with PD. In this study, we evaluated 2 enzymatic markers of oxidative stress, glutathione (GSH) system and superoxide dismutase (SOD), and TL in a Drosophila melanogaster model for PD [phosphatase and tensin homolog‐induced putative kinase 1 ( PINK1 ) B9 ]. This evaluation was also performed after treatment with the phytoextracts. PINK1 B9 mutants showed a decrease in GSH amount and SOD activity and unexpected longer telomeres compared with wild‐type flies. M. pruriens treatment seemed to have a beneficial effect on the oxidative stress conditions. On the other hand, W. somnifera treatment did not show any improvements in the studied oxidative stress mechanisms and even seemed to favor the selection of flies with longer telomeres. In summary, our study suggests the importance of testing antioxidant phytoextracts in a PINK1 B9 model to identify beneficial effects for PD.—Baroli, B., Loi, E., Solari, P., Kasture, A., Moi, L., Muroni, P., Kasture, S., Setzu, M. D., Liscia, A., Zavattari, P. Evaluation of oxidative stress mechanisms and the effects of phytotherapic extracts on Parkinson's disease Drosophila PINK1 B9 model. FASEB J. 33, 11028–11034 (2019). www.fasebj.org


  • Open Access

    Standardized phytotherapic extracts rescue anomalous locomotion and electrophysiological responses of TDP-43 Drosophila melanogaster model of ALS

    by Riccardo Maccioni, Maria Dolores Setzu, Giuseppe Talani, Paolo Solari, Ameya Kasture, Sonja Sucic, Simona Porru, Patrizia Muroni, Enrico Sanna, Sanjay Kasture, et al.

    Findings from studies using animal models expressing amyotrophic lateral sclerosis (ALS) mutations in RNA-binding proteins, such as Transactive Response DNA-binding protein-43 (TDP-43), indicate that this protein, which is involved in multiple functions, including transcriptional regulation and pre-mRNA splicing, represents a key candidate in ALS development. This study focuses on characterizing, in a Drosophila genetic model of ALS (TDP-43), the effects of Mucuna pruriens (Mpe) and Withania somnifera (Wse). Electrophysiological and behavioural data in TDP-43 mutant flies revealed anomalous locomotion (i.e. impaired climbing with unexpected hyperactivity) and sleep dysregulation. These features, in agreement with previous findings with a different ALS model, were at least partially, rescued by treatment with Mpe and Wse. In addition, electrophysiological recordings from dorsal longitudinal muscle fibers and behavioral observations of TDP-43 flies exposed to the volatile anaesthetics, diethyl ether or chloroform, showed paradoxical responses, which were normalized upon Mpe or Wse treatment. Hence, given the involvement of some potassium channels in the effects of anaesthetics, our results also hint toward a possible dysregulation of some potassium channels in the ALS-TDP-43 Drosophila model, that might shed new light on future therapeutic strategies pertaining to ALS.


  • Open Access

    Big Lessons from Tiny Flies: Drosophila melanogaster as a Model to Explore Dysfunction of Dopaminergic and Serotonergic Neurotransmitter Systems

    by Ameya Sanjay Kasture, Thomas Hummel, Sonja Sucic, Michael Freissmuth

    The brain of Drosophila melanogaster is comprised of some 100,000 neurons, 127 and 80 of which are dopaminergic and serotonergic, respectively. Their activity regulates behavioral functions equivalent to those in mammals, e.g., motor activity, reward and aversion, memory formation, feeding, sexual appetite, etc. Mammalian dopaminergic and serotonergic neurons are known to be heterogeneous. They differ in their projections and in their gene expression profile. A sophisticated genetic tool box is available, which allows for targeting virtually any gene with amazing precision in Drosophila melanogaster. Similarly, Drosophila genes can be replaced by their human orthologs including disease-associated alleles. Finally, genetic manipulation can be restricted to single fly neurons. This has allowed for addressing the role of individual neurons in circuits, which determine attraction and aversion, sleep and arousal, odor preference, etc. Flies harboring mutated human orthologs provide models which can be interrogated to understand the effect of the mutant protein on cell fate and neuronal connectivity. These models are also useful for proof-of-concept studies to examine the corrective action of therapeutic strategies. Finally, experiments in Drosophila can be readily scaled up to an extent, which allows for drug screening with reasonably high throughput.


  • Open Access

    A behavioral task with more opportunities for memory acquisition promotes the survival of new neurons in the adult dentate gyrus

    by Ida E. J. Aasebø, Ameya Sanjay Kasture, Marzia Passeggeri, Ayumu Tashiro

    It has been suggested that the dentate gyrus, particularly its new neurons generated via adult neurogenesis, is involved in memory acquisition and recall. Here, we trained rats in two types of Morris water maze tasks that are differentially associated with these two memory processes, and examined whether new neurons are differently affected by the two tasks performed during the second week of neuronal birth. Our results indicate that the task involving more opportunities to acquire new information better supports the survival of new neurons. Further, we assessed whether the two tasks differentially induce the expression of an immediate early gene, Zif268, which is known to be induced by neuronal activation. While the two tasks differentially induce Zif268 expression in the dentate gyrus, the proportions of new neurons activated were similar between the two tasks. Thus, we conclude that while the two tasks differentially activate the dentate gyrus, the task involving more opportunities for memory acquisition during the second week of the birth of new neurons better promotes the survival of the new neurons.